ALT 803

Drug Profile

ALT 803

Alternative Names: ALT-803; IL-15N72D:IL-15RαSu/Fc fusion protein complex

Latest Information Update: 05 May 2017

Price : $50

At a glance

  • Originator Altor BioScience Corporation; NantKwest
  • Developer Altor BioScience Corporation; University of Minnesota; University of South Carolina
  • Class Antineoplastics; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants; Interleukin-15 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Bladder cancer
  • Phase I/II Haematological malignancies; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer
  • Phase I HIV infections; Malignant melanoma
  • Preclinical Bacterial infections

Most Recent Events

  • 02 May 2017 Phase-II/III clinical trials in Bladder cancer (Combination therapy) in USA (Intravesicular)
  • 02 May 2017 ALT 803 receives Fast Track designation for Bladder cancer [Intravesicular,Liquid] (Combination therapy) in USA
  • 27 Apr 2017 NantCell plans a phase I/II trial for Solid tumours (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) (NCT03127098)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top